KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Net Margin (2016 - 2025)

Pfizer (PFE) has disclosed Net Margin for 17 consecutive years, with 0.17% as the latest value for Q2 2025.

  • On a quarterly basis, Net Margin fell 65.0% to 0.17% in Q2 2025 year-over-year; TTM through Dec 2025 was 0.04%, a 9.0% increase, with the full-year FY2025 number at 0.04%, down 9.0% from a year prior.
  • Net Margin was 0.17% for Q2 2025 at Pfizer, up from 0.02% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 0.82% in Q2 2024 to a low of 1.81% in Q3 2024.
  • A 5-year average of 0.26% and a median of 0.03% in 2024 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: plummeted -873bps in 2021, then skyrocketed 137bps in 2022.
  • Pfizer's Net Margin stood at 1.03% in 2021, then skyrocketed by 91bps to 0.09% in 2022, then crashed by -716bps to 0.76% in 2023, then soared by 98bps to 0.02% in 2024, then skyrocketed by 1013bps to 0.17% in 2025.
  • Per Business Quant, the three most recent readings for PFE's Net Margin are 0.17% (Q2 2025), 0.02% (Q4 2024), and 1.81% (Q3 2024).